Расширенный поиск

Генотипический и фенотипический полиморфизм N-ацетилтрансфераз в роли предикторов бронхолегочных заболеваний

Полный текст:

Об авторах

О. А. Яковлева
Винницкий государственный медуниверситет

А. И. Косован
Винницкий государственный медуниверситет

О. В. Дякова
Винницкий государственный медуниверситет

В. В. Царук
Винницкий государственный медуниверситет

Список литературы

1. Бориско А.С., Моргулис О.Г, Яковлева О.А. Состояние процессов ацетилирования у больных с синдромом бронхоспазма. Пульмонология. Респ. Межведомств. сб. 1991; 10: 56-57.

2. Иванова В.В., Аксенов О.А., Кветная А.С. и др. Вируснобактериальные ассоциации и их роль в формировании бронхолегочных заболеваний у детей. Педиатрия 1992; 4-6: 8-12.

3. Ивчик Т.В., Кокосов А.Н., Буловская Л.H. и др. N-ацетилтрансфераза (NAT) — предрасполагающий фактор к развитию хронической обструктивной болезни легких (ХОБЛ). Пульмонология 1998; Прил.: Международный конгресс Интерастма- 98, Москва 20-21 окт. 1998. VIII Национальный конгресс по болезням органов дыхания. Сб. рез.: 440.

4. Кокосов А.Н., Ивчик Т.В., Буловская Л.H. и др. Определение фенотипа N-ацетилтрансферазы по интенсивности ацетилирования у больных хронической обструктивной болезнью легких. Там же. 204.

5. Ляхович В.В., Вавилин В.А., Гупгкина И.И. и др. Фармакологический и фармакогенетический подходы к проблемам патогенеза и фармакотерапии экологически обусловленных заболеваний. В кн.: V Российский нац. конгресс "Человек и лекарство". М.; 1998. 334.

6. Родцевич О.Г. Роль гено- и фенотипических маркерных систем в прогнозе детской астмы. В кн.: 7-й Национальный конгресс по болезням органов дыхания. М.; 1997. 82.

7. Рудинский К.А., Буловская Л.Н., Линцов А.Е. Характеристика активности полиморфной N-ацетилтрансферазы у больных бронхиальной астмой. Там же. 120.

8. Яковлева О.А., Косован А.И., Пентюк А.А. Индивидуальные особенности ацетилирования тест-препаратов при бронхообструктивном синдроме. В кн.: Клиническая фармакология - 25 лет: Материалы международной конф. М.; 1997. 96.

9. Agendes J.A., Marthnez С., Olivera М. et al. Identification and prevalens study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996; 6(5): 423-428.

10. Ambrosone C.B., Freudenheim J.L.., Graham S. et al. Cigarrette smoking, N-acetyltrasferase 2 genetic polymorphisms and breast cancer risk. J.A.M.A. 1996; 276 (18): 1494-1501.

11. Badawi A.F., Stern S.J., Lang N.P. et al. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogenDNA adduct levels and human cancer susceptibility. Progr. Clin. Biol. Res. 1996; 395: 109-140.

12. Bell D.A., Taylor J.A., Butler M.A. et al. Genotype/phenotype discordans for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in AfricanAmericans. Carcinogenesis 1993; 14 (8): 1689-1692.

13. Boobis A.R. Molecular basis for differences in suspectibility to toxicants: introduction. Toxicol. Lett. 1992; 64-65 (spec. No): 109-113.

14. Bosso S.A., Liu Q., Evans W.E. et al. CYP2D6, N-acetylation and xanthine oxidase activity in cystic fibrosis. Pharmacotherapy 1996; 16 (5): 749-753.

15. Carr A., Gross A.S., Hoskins J.M. et al. Acetylation genotype and cutaneous hypersensitivity to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1994; 8 (3): 333-337.

16. Carrillo J.A., B enthez 3. Caffein metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin. Pharmacol. Ther. 1994; 55 (3): 293-304.

17. Cascorbi I., Brockm yller J., M rozikiew icz P.M. et al. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res. 1996; 56(17): 3961-3966.

18. Cofta S., Lowiski Z., M ynarczyc W. Acetylation phenotype in patients with lung cancer. Pneumonol. Alergol. Pol. 1995; 63 (7-8): 407-409.

19. Cribb А.Б., Isbruker K., Levatte T. et al. Acetylator phenotyping: the urinary caffein metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 1994; 4 (3): 166-170.

20. Dargel K. Metabolism of leukotrienes is impaired in hepatocytes from rats with thioacetamide-induced liver cirrhosis. Prostagland. Leucot. Essent. Fatty Acids. 1995; 53(4): 309-314.

21. Deguchi T. Molecular pharmacology of polymorphic aryiamine N-acetyltransferase involved in the metabolism of aryiamine drugs. Nippon Rinsho 1992; 50 (4): 877-886.

22. Denzlinger C., Haberl C., Wilmanns W. Cystenyl leukotriene production in anaphylactic reactions. Int. Arch. Allergy Immunol. 1995; 108(2): 158-164.

23. Dietrich A, Kawakubo Y., Rzany B. et at. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp. Dermatol. 1995; 4 (5): 313-316.

24. Goldstein J.A., Faletto M.V. Advances in mechanisms of activation and deactivation of environmental chemicals. Environ. Hlth Perspect. 1993; 100: 169-176.

25. Hamelin B.A., Xu K., Vally F. et al. Caffeine metabolism in cystic fibrosis: enhansed xanthine oxidase activity. Ibid. 56 (5): 521-529.

26. Hein D.W ., Doll M .A., Rustan T.D. et al. Metabolic activation and deactivation of aryiamine carcinogens by human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14 (8): 1633-1638.

27. Hickman D., Risch A., Bell D.A. et al. Chromosomal localization of human genes for aryiamine N-acetyltransferase. Biochem. J. 1994; 297 (pt 3): 441-445.

28. Hirvonen A., Saarikoski S.T., Linnainmaa K. et al. GlutationS-transferase and N-acetyltransferase genotypes and asbestosassociated pulmonary disoder. J. Natl. Cancer Inst. 1996; 88 (24): 1853-1856.

29. Hou S.M ., Lambert B., Hemminski K. Relationship between mutant frequency, aromatic DNA adducts and genotypes for GSTM1 and NAT2 in bus maintenance workers. Carcinogenesis 1995; 16 (8): 1913-1917.

30. Hsu K.Y., Song D.J., Ho Y. The influence of pyruvic acid the phnrmacokinetics of sulphadiazine in rabbits. Biopharm. Drug Dispos. 1995; 16 (3): 233-244.

31. Hussein E., Yamamah O., Saleh A. Glucose-6-phosphate dehydrogenase defiscency and sulfadimidin acetylation phenotypes in Egyptian oases. Biochem. Genet. 1992; 30 (3-4): 113-121.

32. Hutabarat B.M., Sm ith A.L., Unadkat D.J. Disposition of drugs in cystic fibrosis, VII. Acetylation of sulphamethoxazol in blood cells: in vitro-in vivo correlation and characterzation of its kinetics of acetylation in lymphocytes. Clin. Pharmacol. Ther. 1994; 55(4): 427-433.

33. Ilett K.F, Chiswell O.M., Spargo K.M. et al. Acetylation phenotype and genotype in aboriginal leprosy petiens from the north-west region of Western Australia. Ibid. 1993; 3 (5): 264-269.

34. Kaufmann G.R., Wenk M., Taeschner W. et al. N-acetyltransferase 2 polymorphism in patients infected with human immunodefisiency virus. Clin. Pharmacol. Ther 1996; 60 (1): 62-67.

35. Lin H J., Han C. Y., Lin B.K. et al. Ethnie distribution of slow acetylator mutation in the polymorphic N-acetyltransferase (NAT2) gene. Ibid. 1994; 4 (3): 125-134.

36. Magazine H.I., Malik A.B., Beuner C.A. et al. Acetylated endotelin-l is a constrictor in guinea pig lung vasculature but not in isolated vascular strips. J. Pharmacol. Exp. Ther. 1992; 260 (2): 632-636.

37. Marthnez C., Agendez J.A., Olivera M et al. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995; 5 (4): 207-214.

38. Mathelier-Fusade P., Leynadier F. Intolerance to sulfonamides in HIV infected subjects. Toxic and allergic origin. Presse Med. 1993; 22 (29): 1363-1365.

39. Meyer U.A. Polymorphism of human acetyltransferases. Ibid. 1994; 102 (suppl.6): 213-216.

40. Mrosikievicx P.M., Cascorbi I., Roots I. et al. Determination and allelic allocation of seven nucleotide transitions within the aryiamine N-acetyltransferase gene in the Polish population. Clin. Pharmacol. Ther. 1996; 59 (4): 376-382.

41. Hebert D.W ., McKinnon R.A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of tox

42. Nerurkar P.V., Schut H.A., Anderson L.M. et al. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo [4,5-f] quinoline in the absence of cytochrome P450 induction. Mol. Pharmacol. 1996; 49 (5): 874-881.

43. O'Brien P.J., Hales B.F., Josephy P.D. et al. Chemical carcinogenesis, mutagenesis and teratogenesis. Can. J. Physiol. Pharmacol. 1996; 74 (5): 565-571.

44. Oyama Т., Kawamoto Т., Mizoue T. et al. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Res. 1997; 17 (18): 577-581.

45. Pontes Z.B., Vinsent-Viry М., Gueguen K. et al. Acetylation phenotypes and biological variation in a French Caucasian population. Eur. J. Clin. Chem. Clin. Biochem. 1993; 31 (2): 59-68.

46. Rashid J.R., Kofi-Tsepko, Juma F.D. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital. East Afr. Med. J. 1992; 69 (7): 406-408.

47. Raunio H., Husggafvel-Pursiainen K., Anttila S. et al. Diagnosis of polymorphysms in carcinogen-activating and inactivating enzymes and cancer susceptibility — a reivew. Gene 1995; 159 (1): 113-121.

48. Roots I., Brockmyller J., Drakoulis N. et al. Mutant genes of cytochrome P-450IID6, glutathion S-transferase class Mu and aryiamine N-acetyltransferase in lung cancer patients. J. Clin. Invest. 1992; 70 (3—4): 307-319.

49. Rothman М., Hayers R.B., Bi W: et al. Correlation between Nacetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993; 3 (5): 250-255.

50. Rothman N., Hayers K.B. Using biomarkers of genetic susceptibility to enhance the study of cancer etiology. Environ. Hlth Perspect. 1995; 103 (suppl.8): 291-295.

51. Sardas S., Lahijany B., Cok I. et al. N-acetylation phenotyping with sulfamethazine in an Iranian population. Pharmacogenetics 1993; 3 (3): 131-134.

52. Sinclair J., Sim E. A fragment consisting of first 204 amino-terminal aminoacids of human aryiamine N-acetyltransferase one (NAT1) and the first transacetylation step of catalysis. Biochem. Pharmacol. 1997; 53 (1): 11-16.

53. Sinues B., Ruena P., Benthez J. et al. Thioether excretion, urinary mutagenicity and metabolic phenotype in smokers. J. Toxicol. Environ. Hlth 1994; 43 (3): 327-338.

54. Soon S.L., Mazuruk K., Bernard M. et al. The human serotonin N-acetyltransferase (EC gene (AANAT): structure, chromosomal localization and tissue expression. Genomics 1996; 34 (1): 76-84.

55. Vatsis K.P., Weber W.W., Bell D.A. et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5 (1): 1-17.

56. Vineis P., Landi M .T., Caporaso N. Metabolic polymorphysm and the cancer risk: the evaluation of epidemiological studies. Med. J. Lavoro. 1992; 83 (6): 557-575.

57. Vineis P., Schulte P.A. Scientific and ethical aspects of genetic screening of workers for cancer risk the case of the N-acetyltransferase phenotype. J. Clin. Epidemiol. 1995; 48 (2): 189-197.

58. Watanabe M. Genetic and phenotypic polymorphysms in carcinogen-metabolizing enzymes and cancer susceptibility. Nippon Rinsho 1996; 54 (8): 2261-2275.

59. Weber W.W. Influence of heredity on human sensitivity to environmental chemicals. Environ. Mol. Mutagen. 1995; 25(suppl.26): 102-114.

60. Yadav S.P., Rawitch A.B. Effect of peptide acetylation on its interaction with antipeptide antibody. Biochem. Biophys. Res. Commun. 1994; 205 (3): 1688-1695.

61. Yasunara H. Ethnic factors in evaluation of drug efficacy and safety // Nippon Yagurigaku Zasshi 1994; 104 (2): 67-78.

62. Yiamouyiannis C.A., Sanders B.A., W atkins J.B. et a l . Chronic physical activity: hepatic hypertrophy and increased total biotransformation enzyme activity. Biochem. Pharmacol. 1992; 44 (1): 121-127.

63. Zaher H., Svensson C.K. Glucocorticoid induction of hepatic acetyl-CoA:arylamine N-acetyltransferase activity in the rat. Res. Commun. Chem. Pathol. Pharmacol. 1994; 83 (2): 195-208.


Для цитирования:

Яковлева О.А., Косован А.И., Дякова О.В., Царук В.В. Генотипический и фенотипический полиморфизм N-ацетилтрансфераз в роли предикторов бронхолегочных заболеваний. Пульмонология. 2003;(4):115-121.

For citation:

Yakovleva O.A., Kosovan A.I., Dyakova O.V., Tsaruk V.V. Genotypic and phenotypic polymorphism of N-acetyltransferase as predictors of bronchopulmonary diseases. PULMONOLOGIYA. 2003;(4):115-121. (In Russ.)

Просмотров: 23

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)